{"id":"MIPSS70.v0.0.1","gdl_version":"2.1","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Kevin Arjona","email":"kevin.arjona@cambio.se","organisation":"Cambio CDS","date":"2025-04-24"},"lifecycle_state":"Author draft","details":{"en":{"id":"en","purpose":"To calculate the total points for the MIPSS70 and/or MIPSS70+ v2.0 scores and to interpret the resulting score(s) into prognostic risk categories (e.g., Very Low, Low, Intermediate, High, Very High).","use":"To be used with the openEHR-EHR-OBSERVATION.mipss70.v0 archetype. Calculates the MIPSS70 score by summing points: 1 point each for Age &gt;70, Constitutional symptoms, Hb &lt;10, WBC &gt;25, Platelets &lt;150, Blasts ≥2%, BM fibrosis ≥2. Calculates the MIPSS70+ v2.0 score by starting with the MIPSS70 points and adding/subtracting points for genetic factors: +1 for U2AF1 Q157, -2 for CALR type 1/like, +2 for 1 HMR mutation, +3 for ≥2 HMR mutations (replaces the +2). Maps the calculated total score(s) to risk categories as defined in the original publications: MIPSS70 (Very Low: 0, Low: 1-2, Int: 3-4, High: ≥5); MIPSS70+ v2.0 (Very Low: 0-1, Low: 2-4, Int: 5-7, High: 8-9, Very High: ≥10).","misuse":"Not applicable for interpretation if required input data from the OBSERVATION.mipss70 archetype is missing. Do not use to generate risk stratification for other scoring systems (e.g., DIPSS, IPSS).","copyright":"© Cambio CDS","keywords":["mipss70","mipss70+","primary myelofibrosis"]}},"other_details":{"references":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9. PMID: 29226763.\n\nTefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30. PMID: 29708808.","en":"Calculates the MIPSS70 and MIPSS70+ v2.0 scores and provides corresponding risk stratification based on recorded clinical, laboratory, and genetic parameters for patients with primary myelofibrosis."},"other_contributors":[]},"definition":{"data_bindings":{"gt0002":{"id":"gt0002","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.mipss70.v0","template_id":"openEHR-EHR-OBSERVATION.mipss70.v0","elements":{"gt0003":{"id":"gt0003","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0053]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0054|Available|","local::at0055|Not available|"]},"gt0004":{"id":"gt0004","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0007]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0008|No|","1|local::at0009|Yes|"]},"gt0005":{"id":"gt0005","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0010]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0011|No|","2|local::at0012|Yes|"]},"gt0006":{"id":"gt0006","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0014|No|","2|local::at0015|Yes|"]},"gt0007":{"id":"gt0007","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0016]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0017|No|","1|local::at0018|Yes|"]},"gt0008":{"id":"gt0008","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0019]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0020|No|","1|local::at0021|Yes|"]},"gt0009":{"id":"gt0009","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0022]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0023|No|","1|local::at0024|Yes|"]},"gt0010":{"id":"gt0010","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0025]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0026|No|","1|local::at0027|Yes|"]},"gt0011":{"id":"gt0011","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0028]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0029|No|","1|local::at0030|Yes|"]},"gt0012":{"id":"gt0012","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0031]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0032|No|","2|local::at0033|Yes|"]},"gt0013":{"id":"gt0013","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0034]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0035|≥11 mg/dL (men), ≥10 mg/dL (women)|","1|local::at0036|9-10.9 mg/dL (men), 8-9.9 mg/dL (women)|","2|local::at0037|<9 mg/dL (men), <8 mg/dL (women)|"]},"gt0014":{"id":"gt0014","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0047]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0048|No|","3|local::at0049|Yes|"]},"gt0015":{"id":"gt0015","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0050]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0051|No|","4|local::at0052|Yes|"]}}},"gt0016":{"id":"gt0016","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.mipss70.v0","template_id":"openEHR-EHR-OBSERVATION.mipss70.v0","elements":{"gt0017":{"id":"gt0017","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0056]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0057|Very Low|","local::at0058|Low|","local::at0059|Intermediate|","local::at0060|High|","local::at0061|Very High|"]},"gt0018":{"id":"gt0018","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0062]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0063|N/A|","local::at0064|27.7|","local::at0065|10.3|","local::at0066|7.1|","local::at0067|7.0|","local::at0068|3.5|","local::at0069|2.3|","local::at0070|1.8|"]},"gt0019":{"id":"gt0019","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0071]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0072|MIPSS70+ v2.0 Score|","local::at0073|MIPSS70|"]},"gt0020":{"id":"gt0020","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0074]","data_type":"DV_COUNT"}}}},"templates":{},"rules":{"gt0022":{"id":"gt0022","priority":16,"then":["$gt0020|Total points|.count = $gt0004|Hemoglobin <10 g/dL|.value + $gt0005|Platelet count <100,000 /µL|.value + $gt0006|Leukocyte count >25,000  /µL|.value + $gt0007|Circulating blasts ≥2%|.value + $gt0008|Fibrosis grade ≥2|.value + $gt0009|Constitutional symptoms|.value + $gt0010|Absence of CALR type 1-like mutation|.value + $gt0011|HMR category|.value + $gt0012|Two or more HMR mutations|.value","$gt0019|Score| = local::at0073|MIPSS70|"],"when":["$gt0003|Karyotype information| == local::at0055|Not available|"]},"gt0021":{"id":"gt0021","priority":15,"then":["$gt0019|Score| = local::at0072|MIPSS70+ v2.0 Score|","$gt0020|Total points|.count = $gt0013|Hemoglobin, mg/dL|.value + $gt0009|Constitutional symptoms|.value + $gt0010|Absence of CALR type 1-like mutation|.value + $gt0011|HMR category|.value + $gt0012|Two or more HMR mutations|.value + $gt0014|Unfavorable karyotype|.value + $gt0015|Very high-risk karyotype|.value"],"when":["$gt0003|Karyotype information| == local::at0054|Available|"]},"gt0023":{"id":"gt0023","priority":8,"then":["$gt0017|Risk MIPSS70| = local::at0058|Low|","$gt0018|Median Overall Survival| = local::at0064|27.7|"],"when":["$gt0003|Karyotype information| == local::at0055|Not available|","$gt0020|Total points| <= 1"]},"gt0024":{"id":"gt0024","priority":7,"then":["$gt0017|Risk MIPSS70| = local::at0059|Intermediate|","$gt0018|Median Overall Survival| = local::at0066|7.1|"],"when":["$gt0003|Karyotype information| == local::at0055|Not available|","$gt0020|Total points| >= 2 && $gt0020|Total points| <= 4"]},"gt0025":{"id":"gt0025","priority":6,"then":["$gt0017|Risk MIPSS70| = local::at0060|High|","$gt0018|Median Overall Survival| = local::at0069|2.3|"],"when":["$gt0003|Karyotype information| == local::at0055|Not available|","$gt0020|Total points| >= 5"]},"gt0026":{"id":"gt0026","priority":5,"then":["$gt0017|Risk MIPSS70| = local::at0057|Very Low|","$gt0018|Median Overall Survival| = local::at0063|N/A|"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0020|Total points| == 0"]},"gt0027":{"id":"gt0027","priority":4,"then":["$gt0017|Risk MIPSS70| = local::at0058|Low|","$gt0018|Median Overall Survival| = local::at0065|10.3|"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0020|Total points| >= 1 && $gt0020|Total points| <= 2"]},"gt0029":{"id":"gt0029","priority":1,"then":["$gt0017|Risk MIPSS70| = local::at0061|Very High|","$gt0018|Median Overall Survival| = local::at0070|1.8|"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0020|Total points| > 9"]},"gt0030":{"id":"gt0030","priority":2,"then":["$gt0017|Risk MIPSS70| = local::at0060|High|","$gt0018|Median Overall Survival| = local::at0068|3.5|"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0020|Total points| >= 5 && $gt0020|Total points| <= 8"]},"gt0031":{"id":"gt0031","priority":3,"then":["$gt0017|Risk MIPSS70| = local::at0059|Intermediate|","$gt0018|Median Overall Survival| = local::at0067|7.0|"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0020|Total points| >= 3 && $gt0020|Total points| <= 4"]},"gt0032":{"id":"gt0032","priority":14,"then":["$gt0020|Total points| = $gt0020|Total points|.count + 1"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0009|Constitutional symptoms| == 1|local::at0024|Yes| || $gt0010|Absence of CALR type 1-like mutation| == 1|local::at0027|Yes| || $gt0011|HMR category| == 1|local::at0030|Yes|"]},"gt0033":{"id":"gt0033","priority":13,"then":["$gt0020|Total points| = $gt0020|Total points|.count + 2"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","( $gt0009|Constitutional symptoms| == 1|local::at0024|Yes| || $gt0010|Absence of CALR type 1-like mutation| == 1|local::at0027|Yes| && $gt0011|HMR category| == 1|local::at0030|Yes| ) || ( $gt0009|Constitutional symptoms| == 1|local::at0024|Yes| && $gt0010|Absence of CALR type 1-like mutation| == 1|local::at0027|Yes| )"]},"gt0034":{"id":"gt0034","priority":9,"then":["$gt0020|Total points| = $gt0020|Total points|.count + 2"],"when":["$gt0003|Karyotype information| == local::at0054|Available|","$gt0012|Two or more HMR mutations| == 2|local::at0033|Yes|"]},"gt0035":{"id":"gt0035","priority":12,"then":["$gt0020|Total points| = $gt0020|Total points|.count + 3"],"when":["$gt0003|Karyotype information| == local::at0054|Available|"," $gt0009|Constitutional symptoms| == 1|local::at0024|Yes| && $gt0010|Absence of CALR type 1-like mutation| == 1|local::at0027|Yes| && $gt0011|HMR category| == 1|local::at0030|Yes| "]},"gt0036":{"id":"gt0036","priority":11,"then":["$gt0020|Total points| = $gt0020|Total points|.count + 4"],"when":["fired ( $gt0032|1 point| )","fired ( $gt0035|3 points| )"]},"gt0037":{"id":"gt0037","priority":10,"then":["$gt0020|Total points| = $gt0020|Total points|.count + 5"],"when":["fired ( $gt0032|2 points| )","fired ( $gt0035|3 points| )"]}}},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"id":"gt0001","text":"Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)","description":"Calculates the MIPSS70 and MIPSS70+ v2.0 scores and provides corresponding risk stratification based on recorded clinical, laboratory, and genetic parameters for patients with primary myelofibrosis."},"gt0002":{"id":"gt0002","text":"openEHR-EHR-OBSERVATION.mipss70.v0"},"gt0003":{"id":"gt0003","text":"Karyotype information"},"gt0004":{"id":"gt0004","text":"Hemoglobin <10 g/dL"},"gt0005":{"id":"gt0005","text":"Platelet count <100,000 /µL"},"gt0006":{"id":"gt0006","text":"Leukocyte count >25,000  /µL"},"gt0007":{"id":"gt0007","text":"Circulating blasts ≥2%"},"gt0008":{"id":"gt0008","text":"Fibrosis grade ≥2"},"gt0009":{"id":"gt0009","text":"Constitutional symptoms"},"gt0010":{"id":"gt0010","text":"Absence of CALR type 1-like mutation"},"gt0011":{"id":"gt0011","text":"HMR category"},"gt0012":{"id":"gt0012","text":"Two or more HMR mutations"},"gt0013":{"id":"gt0013","text":"Hemoglobin, mg/dL"},"gt0014":{"id":"gt0014","text":"Unfavorable karyotype"},"gt0015":{"id":"gt0015","text":"Very high-risk karyotype"},"gt0016":{"id":"gt0016","text":"openEHR-EHR-OBSERVATION.mipss70.v0"},"gt0017":{"id":"gt0017","text":"Risk MIPSS70"},"gt0018":{"id":"gt0018","text":"Median Overall Survival"},"gt0019":{"id":"gt0019","text":"Score"},"gt0020":{"id":"gt0020","text":"Total points"},"gt0021":{"id":"gt0021","text":"Count of points MIPSS70+ v2.0","description":"Count the total of points for MIPSS70+ v2.0 score"},"gt0022":{"id":"gt0022","text":"Count of points MIPSS70","description":"Count the total points for MIPSS70"},"gt0023":{"id":"gt0023","text":"Low risk","description":"MIPSS70"},"gt0024":{"id":"gt0024","text":"Intermediate risk","description":"MIPSS70"},"gt0025":{"id":"gt0025","text":"High risk","description":"MIPSS70"},"gt0026":{"id":"gt0026","text":"Very low risk","description":"MIPSS70+ v2.0"},"gt0027":{"id":"gt0027","text":"Low risk","description":"MIPSS70+ v2.0"},"gt0031":{"id":"gt0031","text":"Intermediate risk","description":"MIPSS70+ v2.0"},"gt0030":{"id":"gt0030","text":"High risk","description":"MIPSS70+ v2.0"},"gt0029":{"id":"gt0029","text":"Very High risk","description":"MIPSS70+ v2.0"},"gt0032":{"id":"gt0032","text":"1 point","description":"Change the values of the  points to apply MIPSS70+ v2.0 "},"gt0033":{"id":"gt0033","text":"2 points","description":"Change the values of the  points to apply MIPSS70+ v2.0 "},"gt0035":{"id":"gt0035","text":"3 points","description":"Change the values of the  points to apply MIPSS70+ v2.0 "},"gt0034":{"id":"gt0034","text":"Two or more HMR mutations","description":"Change the values of the  points to apply MIPSS70+ v2.0 "},"gt0036":{"id":"gt0036","text":"4 points","description":"Change the values of the  points to apply MIPSS70+ v2.0 "},"gt0037":{"id":"gt0037","text":"5 points","description":"Change the values of the  points to apply MIPSS70+ v2.0 "}}}},"term_bindings":{}}}